Abbott has received FDA 510(k) clearance for its new FreeStyle Liteblood glucose test strips that minimise interference during blood glucose testing.
Abbott said that the new FreeStyle Lite test strips do not use GDH-PQQ1 enzyme, which can be affected by common non-glucose sugars. Instead they use a GDH-FAD2 enzyme which is unaffected by common non-glucose sugars, such as maltose or galactose, and minimizes the potential for other interference.3
The new FreeStyle Lite test strips are compatible with all FreeStyle Lite blood glucose monitoring systems, eliminating the need to switch meters. The FreeStyle Lite strips feature a new, easier-to-use ZipWik design tapered test strip that offers a better blood glucose testing experience.
FDA clearance follows Abbott’s recent announcement of European availability of the new FreeStyle Lite test strips. The new FreeStyle Lite test strips are available in 14 European countries. Over the coming months, the new FreeStyle Lite test strips are ezxpected to be available to customers in Australia, Israel and Norway.
Heather Mason, senior vice president of Abbott Diabetes Care, said: “The new FreeStyle Lite test strips represent Abbott’s latest success in delivering innovative products for people living with diabetes. By minimizing interference and providing a better testing experience4, Abbott is delivering on what patients and health care professionals demand in diabetes care, especially for people who use insulin to manage their diabetes.”